Scientific Research
Fortetropin® is at the core of everything we do. We begin by sourcing raw, fertilized chicken egg yolk which then goes through a patented pasteurization process that retains the yolks’ powerful bioactivity while eliminating harmful bacteria. Every step of the process is executed at world class, state of the art facilities with rigorous testing at each stage.
Fortetropin is clinically shown to help build muscle, slow down the rate of muscle loss and improve recovery due to aging, injury or surgery.
Though largely overlooked in the healthcare space, strong muscle is clinically shown to have a significant effect on quality of life, longevity, and recovery among humans and animals.
Our Clinical Studies & Research
Kansas State University
- Fortetropin prevented atrophy of disuse and improved recovery from TPLO surgery.
- Fortetropin resulted in decreased Liverpool Osteoarthritis in Dogs’ (LOAD) scores in geriatric dogs.
University of Tampa
Fortetropin acts by upregulating mTOR pathway (promoting muscle growth), downregulating Ubiquitin pathway (slowing muscle degradation), and lowering myostatin levels (promoting muscle growth).
University of California, Berkeley
Fortetropin increased rate of muscle protein synthesis by 18% in older adults.
McMaster University
In a study involving the unilateral leg immobilization model in young men, Fortetropin supplementation prevented a rise in serum myostatin levels.
North Carolina State University
Study showed that Fortetropin supplementation increased lean muscle mass in 70 percent of test subjects while contributing no adverse side effects.
The Impact of Fortetropin on Safety and Tolerability in Retired Horses
Myogenic atrophy in horses results from several conditions in the horse, such as Cushing’s disease to disuse atrophy secondary to injury, to malnutrition and secondary, to various genetic or immune-mediated myopathies.
Our Patents
- U.S. Patent 10,835,576 entitled “Method of obtaining effective amounts of avian follistatin” with claims to a method of increasing muscle mass in an individual with a muscle degenerating disease associated with wasting of skeletal muscle comprising making and administering a drinkable product comprising avian follistatin and a liquid.
- U.S. Patent 11,433,104 entitled “Avian follistatin product” with claims to a method for increasing muscle mass comprising administering to a subject in need of increased muscle mass a sports nutrition composition comprising at least 1 ng of follistatin per mg of composition and avian egg yolk membrane, wherein the avian egg yolk membrane is dehydrated and free of viable pathogens, and wherein 1 to 200 grams per dose of the sports nutrition composition is administered.
- U.S. Patent 8,815,320 entitled “Process for producing a composition containing active follistatin” with claims to a process for producing a composition comprising biologically active follistatin comprising: providing raw liquid egg yolk, raw liquid whole egg or raw liquid egg white originating from fertilized avian eggs and subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a step of preservation while maintaining the temperature at or below 38° C., wherein the step of preservation is selected from subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a high pressure treatment of at least 4500 bar for at least 1 min, from subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a pulsed electric field treatment of at least 5 kV/cm at a flow rate of 30 L/h, and from a combination of the high pressure treatment and the pulsed electric field treatment to provide a preserved liquid egg yolk, preserved liquid whole egg or preserved liquid egg white.
- U.S. Patent 10,165,785 entitled “Process for producing a composition for increasing muscle mass” with claims to a process for producing a composition for increasing muscle mass comprising: providing raw liquid egg yolk, raw liquid whole egg or raw liquid egg white originating from eggs, diluting with a diluent and then concentrating the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a fraction containing the egg yolk membrane and/or the chalazae, and subjecting the concentrated fraction to a step of preservation while maintaining the temperature at or below 38° C., wherein the step of preservation is selected from subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a high pressure treatment of at least 4500 bar for at least 1 min, from subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a pulsed electric field treatment of at least 5 kV/cm at a flow rate of 30 L/h, and from a combination of the high pressure treatment and the pulsed electric field treatment to provide a preserved liquid egg yolk, preserved liquid whole egg or preserved liquid egg white so that a composition for increasing muscle mass is produced.
- U.S. Patent 11,051,524 entitled “Process for producing a composition for increasing muscle mass” with claims to a process for producing a composition comprising biologically active follistatin or which increases muscle mass, said process comprising diluting with a diluent and then concentrating raw liquid egg yolk, raw liquid whole egg or raw liquid egg white to a fraction containing egg yolk membrane and/or chalazae and subjecting the raw liquid egg yolk, raw liquid whole egg or raw liquid egg white originating from avian egg to a step of preservation comprising high pressure treatment and/or pulsed electric field treatment.
- U.S. Patent 10,925,904 entitled “Methods and compositions for improving skeletal muscle protein fractional synthetic rate” with claims to a method for improving skeletal muscle protein fractional synthetic rate (FSR) in older mammals comprising administering to the older mammal a composition consisting of egg yolk powder and one or more additional agents selected from creatine, Vitamin D, selective androgen receptor molecules, ghrelin agonists, myostatin antibodies, activin IIR antagonists, angiotensin converting enzyme inhibitors, beta antagonists, and fast skeletal muscle troponin activators.
- U.S. Patent 11,318,171 entitled “Methods and compositions for improving skeletal muscle protein fractional synthetic rate” with claims to a method for inhibiting or reversing sarcopenia in a mammal comprising orally administering to the mammal on a daily basis a composition comprising egg yolk powder in an amount ranging from about 50 to about 300 mg/kg/day of said composition.
Featured Studies
CANINE OSTEOARTHRITIS STUDY
As pets age, quality of life and mobility can be impacted by pain of osteoarthritis and age-related muscle atrophy (sarcopenia). The purpose of this randomized, double-blinded, placebo controlled study was to evaluate the effects of Fortetropin®, a nonthermal-pasteurized, freeze-dried, fertilized egg yolk product, on mobility in senior dogs.
TPLO SURGERY STUDY
To determine if a commercial myostatin reducer (Fortetropin®) would inhibit disuse muscle atrophy in dogs after a tibial plateau leveling osteotomy.
Patients were randomly assigned into the Fortetropin® or placebo group and clients were instructed to add the assigned supplement to the dog’s normal diet once daily for twelve weeks. Enrolled patients had ultrasound measurements of muscle thickness, tape measure measurements of thigh circumference, serum myostatin level assays, and static stance analysis evaluated at weeks 0, 8, and 12.
The Impact of Fortetropin® in Cats Suffering from Chronic Kidney Disease
This study was conducted at the North Carolina State University College of Veterinary Medicine and showed that Fortetropin supplementation increased lean muscle mass in 70 percent of test subjects while contributing no adverse side effects. The study was presented at the 2023 AAVN Clinical Nutrition and Research Symposium, Philadelphia, PA.
SERUM MYOSTATIN IN DOGS
To evaluate the effect of a single administration of 6 and 12 g of Fortetropin compared to placebo on serum myostatin in healthy, adult dogs over a 72-h period. The results of this study indicate that administration of single 6 or 12 g dose of Fortetropin does not reduce serum myostatin in healthy adult dogs.